Regression of Optic Disc Neovascularization (NVD) in a Patient with Behçetʼs Disease Treated with Oral Corticosteroids and Adalimumab (ADA)

Klin Monbl Augenheilkd 2019; 236(04): 578-580
DOI: 10.1055/a-0800-8066

Der interessante Fall

Georg Thieme Verlag KG Stuttgart · New York

Regression der Papillenneovaskularisation (NVD) bei einem Patienten mit Behçet-Krankheit unter Behandlung mit oralen Kortikosteroiden und Adalimumab

Authors

Ioannis Papasavvas

¹Ophthalmology, RétinElysée, Lausanne, Switzerland

²Ophthalmology, Clinique de Montchoisi, Centre C, Lausanne, Switzerland
Aude Ambresin

¹Ophthalmology, RétinElysée, Lausanne, Switzerland
Jean-Antoine Pournaras

¹Ophthalmology, RétinElysée, Lausanne, Switzerland
Laure Henchoz

³Ophthalmology, Cabinet dʼOphtalmologie, Moudon, Switzerland
Jean Vaudaux

¹Ophthalmology, RétinElysée, Lausanne, Switzerland

⁴Ophthalmology, Private practice, Morges, Switzerland

References
1 Dick AD, Rosenbaum JT, Al-Dhibi HA. et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis. Fundamentals of Care for UveitiS (FOCUS) initiative. Ophthalmology 2018; 125: 757-773
2 Ming S, Xie K, He H. et al. Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther 2018; 12: 2005-2016
3 Tugal-Tutkun I, Onal S, Altan-Yaycioglu R. et al. Neovascularization of the optic disc in Behçetʼs disease. Jpn J Ophthalmol 2006; 50: 256-265
4 Kawaguchi T, Sugita S, Yamada Y. et al. Regression of optic disc neovascularization in patients with Behçetʼs uveoretinitis after infliximab therapy. J Ocul Pharmacol Ther 2010; 26: 627-630